摘要
目的观察厄贝沙坦氢氯噻嗪复方片剂治疗原发性高血压的有效性和安全性。方法原发性高血压80例,继发性高血压,严重肝、肾功能不全者除外,服用厄贝沙坦氢氯噻嗪,疗程12周。结果 80例中显效48例(60.0%),有效27例(33.75%),无效5例(6.25%),总有效率93.75%,治疗后与治疗前比较,血压明显下降,治疗前为(160±12/100±10)mmHg,治疗后为(130±10/82±10)mmHg。检测24h动态血压,计算降压谷峰比值率>65%。结论厄贝沙坦氢氯噻嗪治疗原发性高血压安全有效,患者依从性好。
Objective To evaluate of the effectiveness and safety of irbesartan/hydrochlorothiazide compound in the treatment of essential hypertension.Methods Eighty cases of essential hypertension were chosen,except for the cases of secondary hypertension and serious liver and kidney dysfunction,course of 12 weeks.Results There were markedly effective in 48 cases（60.0%）,effective in 27 cases（33.75%）,invalid in 5 cases（6.25%）,total effective power 93.75%.Blood pressure decreased significantly after treatment compared with before treatment [before treatment（160±12/100±10）mmHg,after treatment（130±10/82±10）mmHg].24-hour ambulatory blood pressure was detected,and the ratio of buck peak rate was over 65%.Conclusion In the treatment of essential hypertension irbesartan-hydrochlorothiazide is safe and effective and good compliance.
出处
《中国煤炭工业医学杂志》
2011年第7期961-962,共2页
Chinese Journal of Coal Industry Medicine
关键词
高血压
厄贝沙坦
氢氯噻嗪
药物治疗
hypertension
irbesartan-hydrochlorothiazide
curative effect
